Prostate cancer cells may have less vitality after therapy with etomoxir, irreversible inhibitor of CPT1A, and etomoxir treatment in mice reduced xenograft growth for a period of 21 days (Schlaepfer et al., 2014). The gene discussed is CPT1A; the disease is prostate cancer.